Crohn's disease belongs to a group of conditions known as inflammatory bowel diseases (IBD). This chronic condition causes ...
A research team led by Mount Sinai has uncovered mechanisms of abnormal immune cell function that may lead to Crohn's disease ...
The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous ...
MedPage Today on MSN19h
FDA Expands Guselkumab Approval to Crohn's DiseaseThe FDA expanded the approval of guselkumab (Tremfya) to include treatment of moderately to severely active Crohn's disease, ...
Pharmaceutical Technology on MSN1d
FDA approves Johnson & Johnson’s Tremfya to treat Crohn’s diseaseJ&J has received US FDA approval for Tremfya (guselkumab), to treat moderately to severely active Crohn's disease (CD) in ...
The label expansion couls help J&J establish Tremfya as a successor to Stelara, which is now facing a growing biosimilar ...
Zacks Investment Research on MSN1d
J&J's Tremfya Gets FDA Nod for 2nd IBD Condition Crohn's DiseaseJohnson & Johnson JNJ announced that the FDA has granted approval to its key drug, Tremfya, for its second inflammatory bowel ...
In patients with Crohn's disease and intermediate to high preoperative corticosteroid use, primary ileocaecal resection leads ...
Tremfya is also approved to treat patients with plaque psoriasis, active psoriatic arthritis and ulcerative colitis and is ...
June 10, 2024 — Scientists have grown 'mini-guts' in the lab to help understand Crohn's disease, showing that 'switches' that modify DNA in gut cells play an ... Apr. 24, 2024 — Study ...
Johnson & Johnson's Tremfya gains FDA approval for Crohn's disease, backed by Phase 3 trial data and demonstrating ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback